Trial Profile
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Bucindolol (Primary) ; Metoprolol succinate
- Indications Atrial flutter; Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms GENETIC-AF; GENETIC-AF
- Sponsors ARCA biopharma Inc
- 04 Jan 2022 Results published in the ARCA biopharma Media Release.
- 04 Jan 2022 According to an ARCA biopharma media release, data from this study published in in Heart Rhythm O2, a publication of the Hearth Rhythm Society.
- 28 Jul 2021 According to an ARCA biopharma media release,new analysis of the Gencaro Phase 2b data on atrial fibrillation (AF) burden and rhythm control interventions has been published in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association.